✦ LIBER ✦

Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib

✍ Scribed by Cortes, Jorge E.; Nicolini, Franck E.; Wetzler, Meir; Lipton, Jeffrey H.; Akard, Luke; Craig, Adam; Nanda, Nisha; Benichou, Annie-Claude; Leonoudakis, Janis; Khoury, H. Jean; Hochhaus, Andreas; Baccarani, Michele; Kantarjian, Hagop M.

Book ID: 121189963
Publisher: Elsevier
Year: 2013
Tongue: English
Weight: 246 KB
Volume: 13
Category: Article
ISSN: 2152-2650
DOI: 10.1016/j.clml.2013.03.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Significance of deeper molecular respons

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

✍ Falchi, Lorenzo; Kantarjian, Hagop M.; Wang, Xuemei; Verma, Dushyant; Quintás-Ca 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 358 KB

Rates of peripheral arterial occlusive d

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis

✍ Giles, F J; Mauro, M J; Hong, F; Ortmann, C-E; McNeill, C; Woodman, R C; Hochhau 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 253 KB

The Achievement of a 3-Month Complete Cy

The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure

✍ Jabbour, Elias; Kantarjian, Hagop; Ghanem, Hady; O'Brien, Susan; Quintas-Cardama 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 305 KB

Phase III, Randomized, Open-Label Study

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

✍ Cortes, J. E.; Baccarani, M.; Guilhot, F.; Druker, B. J.; Branford, S.; Kim, D.- 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 166 KB

Long-term response to imatinib is not af

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study

✍ Baccarani, Michele; Druker, Brian J.; Branford, Susan; Kim, Dong-Wook; Pane, Fab 📂 Article 📅 2014 🏛 Carden Jennings Publishing 🌐 English ⚖ 340 KB